Introduction
============

Lung cancer and pulmonary tuberculosis (TB) are two major public health issues associated with significant morbidity and mortality. Lung cancer is the leading cause of cancer-related deaths worldwide \[[@b1-crt-2018-084]\]. It accounts for approximately 23% of all cancer deaths and 88,655 patients died from lung cancer during period of 2008 to 2012 in Korea \[[@b2-crt-2018-084]\]. Lung cancer has been associated with a variety of benign lung conditions such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and TB \[[@b3-crt-2018-084]-[@b5-crt-2018-084]\]. TB is one of the major causes of death among infectious diseases. In 2016, 10.4 million people fell ill with TB and 1.8 million died from the disease worldwide according to the World Health Organization \[[@b6-crt-2018-084]\].

Several prospective and retrospective studies have suggested that TB is associated with an increased risk of lung cancer \[[@b7-crt-2018-084]-[@b9-crt-2018-084]\]. Chronic inflammation leading to imbalance in DNA damage and repair mechanisms may be a possible pathophysiology of lung cancer in TB patients. A study showed that chronic airway inflammation promoted lung cancer development in a *KRAS*--mutated mouse model \[[@b10-crt-2018-084]\]. Moreover, chronic pulmonary TB infection resulted in dysplasia and squamous cell carcinoma of lung following accumulation of genomic alterations and dysregulation of growth factors \[[@b11-crt-2018-084]\].

Epidermal growth factor receptor (EGFR) gene encodes signaling proteins crucial for cell proliferation and survival, and *EGFR* mutations are major driver mutations occurring in lung adenocarcinomas \[[@b12-crt-2018-084]\]. Approximately 15% of white patients and 30%-40% of Asian patients with lung adenocarcinoma carried tumors harboring *EGFR* mutations \[[@b13-crt-2018-084]\]. Deletion of exon 19 and L858R point mutations in exon 21 are the most common gene alterations in patients with lung adenocarcinoma. The tumors harboring these mutations showed dramatic response rates (73%-91%) and prolonged progression-free survival (PFS) (7.7-13.3 months) when treated with EGFR tyrosine kinase inhibitors (TKIs) \[[@b14-crt-2018-084]-[@b16-crt-2018-084]\]. The *EGFR* mutations are more frequent in women, East-Asian and never smokers \[[@b17-crt-2018-084]\]. Interestingly, previous studies suggested the possible association between chronic inflammation and EGFR signaling. Casalino-Matsuda et al. \[[@b18-crt-2018-084]\] showed that oxidant-induced goblet cell metaplasia in human bronchial epithelial cells induces *EGFR* activation. In addition, TBinduced overexpression of epiregulin is associated with invasiveness of *EGFR*-mutated cell \[[@b19-crt-2018-084]\]. However, there is scarce data whether pulmonary TB was associated with increased frequency of driving mutations and its role in clinical outcome of patients with lung cancer.

As Korea is among countries with the highest prevalence of TB in general population and *EGFR* mutation frequency in lung cancer, it is plausible that frequent *EGFR* mutations may be attributed to high TB prevalence. Thus, we investigated whether previous pulmonary TB affects the *EGFR* mutational status or clinical outcomes of the patients with pulmonary adenocarcinoma.

Materials and Methods
=====================

1. Patients and data collection
-------------------------------

We retrospectively screened patients with histologically or cytologically confirmed pulmonary adenocarcinoma who were diagnosed and treated at Dongnam Institute of Radiological & Medical Sciences, a secondary referral hospital in Busan, South Korea, from January 2008 through December 2015. Patients with the results of *EGFR* mutation testing available were included in this study. We excluded patients who had active pulmonary TB along with lung cancer and who were diagnosed with other cancers within 5 years since lung cancer diagnosis, as their clinical course may be influenced by those comorbidities. We reviewed the electronic medical records to obtain demographic and clinical data including age, sex, Eastern Cooperative Oncology Group (ECOG) performance status, smoking status, TNM stage, systemic or pulmonary comorbidities and tumor mutational status. All patients underwent chest computed tomography, brain magnetic resonance imaging, and ^18^F-fluorodeoxyglucose positron-emission tomography (PET) for clinical staging determined according to the International Association for the Study of Lung Cancer TNM staging classification of nonsmall cell lung cancer \[[@b13-crt-2018-084]\]. Tumor response was examined by computed tomography (CT) every two cycles of systemic treatment and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 \[[@b20-crt-2018-084]\]. In case of EGFR-TKIs, a single cycle comprised 4 weeks of treatment.

We reviewed initial chest CT scan at diagnosis to determine concomitant old TB lesions. We divided our lung cancer population into two groups: patients with old TB lesions (TB group) and those without lesions (non-TB group). Old TB lesions were defined as at least one of the following as previously described \[[@b21-crt-2018-084]\]: fibrotic scar with volume loss, fibronodular lesions, calcified or non-calcified granulomas, or pleural thickening. The existence and location of old TB lesions were determined based on the consensus of two independent reviewers (I.K. Hwang and S.S. Paik). In case of ambiguous findings, consensus was arrived at after discussion with a chest radiologist at our institution. In case of difficult diagnosis of old TB lesions and lung cancer-related or metastatic lesions based on chest CT, the final decision was made by comparison of the corresponding images with those of PET. To exclude patients with active pulmonary TB, we confirmed the negative results of polymerase chain reaction for TB, acid-fast bacilli staining and TB culture using sputum or bronchial washing specimens obtained at the time of lung cancer diagnosis.

2. *EGFR* mutation testing
--------------------------

Genomic DNA was extracted from formalin-fixed, paraffin-embedded, 5-μm-thick tissue sections using the High Pure polymerase chain reaction (PCR) Template Preparation Kit (Roche Applied Science, Mannheim, Germany) according to the manufacturer's instructions. The extracted DNA was stored at --20°C until analysis. EGFR Pyro Kit (QIAGEN Korea Ltd., Seoul, Korea) and PyroMark Q24 System (QIAGEN Korea Ltd.) were used to detect *EGFR* mutations by real-time PCR. The primer sets cover mutations or deletions spanning exons 18 to 21 of the genes encoding tyrosine kinase domain of *EGFR*. Details of these methods were described in a previous study \[[@b22-crt-2018-084]\].

3. Statistical analyses
-----------------------

Statistical analyses were performed using the SPSS ver. 20.0 software for Windows (IBM Corp., Armonk, NY). PFS was defined as the time from the first day of chemotherapy to disease progression or death from any cause. Overall survival (OS) was defined from the start day of systemic treatment for advanced disease or the day of surgical resection for early-stage disease to death from any cause. Associations between categorical variables were compared using the chisquared test. Associations between clinicopathological parameters and survival were evaluated by univariate analysis using the log-rank test. Subsequently, multivariate Cox proportional hazards regression analysis was conducted after adjusting for parameters with p-values of \< 0.2 in the univariate analysis. Survival probability was estimated by the Kaplan-Meier method. A p-value of \< 0.05 was considered statistically significant.

4. Ethical statement
--------------------

Informed consents were obtained from all patients alive and the study protocol was approved by the Institutional Review Board of the Dongnam Institute of Radiological & Medical Sciences (D-1705-002-002).

Results
=======

1. Patient characteristics
--------------------------

During the study period, 513 patients were diagnosed as lung adenocarcinoma at our institution. After exclusion of patients with cancers other than lung cancer (n=11), active pulmonary TB at the initial diagnosis (n=2) and without any available data for tumor *EGFR* mutational status (n=23), 477 patients were found eligible for this study. The clinicopathological characteristics of the patients are summarized in [Table 1](#t1-crt-2018-084){ref-type="table"}. All subjects were Korean with a median age of 64 years (range, 38 to 84 years). Old TB lesions on chest CT scan were detected in 100 patients (21%, TB group) while no TB lesions in 377 patients (79%, non-TB group). 280 patients (58%) were male, 173 patients (36%) were above the age of 65 years and 272 patients (57%) were current or former smokers. 395 patients (83%) had ECOG performance status of 0 or 1, and 252 patients (53%) were stage IIIB or IV. Tests for anaplastic lymphoma kinase (ALK) translocation including immunohistochemistry and fluorescence *in situ* hybridization were performed in 238 patients (50%), while *KRAS* mutation testing was performed in 199 patients (42%); 10 patients (4%) were positive for *ALK* translocation and 22 patients (11%) were positive for *KRAS*mutation. 270 patients (57%) had more than one systemic comorbidity including hypertension and diabetes while 64 patients (13%) had benign lung diseases other than TB. One hundred fortyseven patients (30%) received EGFR-TKIs during their clinical course.

2. Comparison of *EGFR* mutational status
-----------------------------------------

Overall, 183 patients (39%) carried *EGFR*-mutated tumors. The most frequent mutation was deletion in exon 19 (50%) followed by L858R point mutation (43%). The frequency of *EGFR* mutations was significantly higher in the TB group than in the non-TB group (56/100, 56% vs. 127/377, 34%; p=0.038). In addition, the frequency of exon 19 deletion in the TB group was significantly higher than in the non-TB group (33/100, 33% vs. 60/377, 16%; p=0.011), while the frequency of L858R point mutation was not different between the two groups (20/100, 20% vs. 58/377, 15%; p=0.254) ([Table 1](#t1-crt-2018-084){ref-type="table"}).

3. Multivariate analysis for the prediction of *EGFR* mutation
--------------------------------------------------------------

To determine the factors associated with the rate of *EGFR* mutation, we performed a multivariate analysis for possible clinical variables. As presented in [Table 2](#t2-crt-2018-084){ref-type="table"}, after adjusting for possible confounders, female sex (odds ratio \[OR\], 1.21; 95% confidence interval \[CI\], 1.05 to 1.86), never smoking (OR, 1.27; 95% CI, 1.12 to 1.98), and old TB lesions (OR, 1.43; 95% CI, 1.08 to 2.47) were independently associated with an increased rate of *EGFR* mutation.

4. Association between *EGFR* mutation and the location of old TB lesion
------------------------------------------------------------------------

To investigate the relationship between *EGFR* mutations and location of old TB lesions, we analyzed the frequency of *EGFR* mutations according to the spatial relationship between the primary lung mass and old TB lesions. As summarized in [Table 3](#t3-crt-2018-084){ref-type="table"}, among 100 patients in the TB group, 38 (38%) and 36 patients (36%) had the main tumor mass in the same lobe and different lobe of the ipsilateral lung containing the main TB lesion, respectively, while 26 patients (26%) had main tumor mass in the contralateral lung. The frequency of *EGFR* mutation in patients who had the main mass in the same lobe and different lobe of the ipsilateral lung with the main TB lesion were 61% (23 among 38 patients) and 72% (26 among 36 patients), respectively, while that of those who had lung cancer in the contralateral lung is 27% (7 among 26 patients). The difference in *EGFR* mutational frequencies according to the location of lung cancer and TB lesions was statistically significant (p=0.028). In case of exon 19 deletion, the frequency in patients who had the main mass in the same lobe and different lobe of the ipsilateral lung with the main TB lesion were 57% (17 among 30 patients) and 52% (14 among 27 patients), respectively, whereas that of those who had lung cancer in the contralateral lung is 10% (2 among 20 patients). The difference in the frequencies of exon 19 deletion according to the location of lung cancer and TB lesions was also statistically significant (p=0.013).

5. Survival analyses for overall population and sub-population according to *EGFR* mutational status
----------------------------------------------------------------------------------------------------

To evaluate whether patients with TB-related lung adenocarcinoma showed different survival rates compared with those without TB lesions, we performed a survival analysis according to clinicopathological parameters of all study subjects. The results of survival analyses are summarized in [Table 4](#t4-crt-2018-084){ref-type="table"}. The median OS in all study subjects was 40.5 months (range, 3.3 to 65.7 months). Univariate analysis revealed that male gender, old age, ever smoking, poor performance status, advanced stage and *EGFR* wild-type were significantly associated with shorter OS. The presence of old TB lesions was not associated with OS (p=0.154). Multivariate analysis showed that poor performance status (hazard ratio \[HR\], 1.67; 95% CI, 1.14 to 2.43), advanced stage (HR, 3.61; 95% CI, 2.31 to 5.64) and *EGFR* wild-type (HR, 1.91; 95% CI, 1.29 to 3.58) were independently associated with shorter OS. We further performed subgroup analyses according to *EGFR* mutational status. However, OS was similar between the two groups regardless of *EGFR* mutational status.

6. Survival analysis of patients receiving EGFR-TKIs as a first-line treatment
------------------------------------------------------------------------------

To investigate whether the pulmonary TB affects the response to TKI treatment, we compared the PFS and OS in patients who were treated with EGFR-TKIs as a first-line treatment in each group. Among all the patients, 88 (18.5%) were treated with EGFR-TKIs such as gefitinib (n=39), erlotinib (n=28), and afatinib (n=21) for locally advanced or metastatic *EGFR*-mutated lung adenocarcinoma. Twenty-one and 67 patients were included in TB group and non-TB group, respectively. As first-line *EGFR*-TKI was approved by Korea Food & Drug Administration at April 2010, the enrolment period for this subgroup was 2010-2015. First-line gefitinib and erlotinib were covered by National Health Insurance System (NHIS) of Korea since April 2011 and March 2013, respectively. Ten patients (4 for gefitinib, 6 for erlotinib) paid for their own first-line *EGFR*-TKI treatment before the reimbursement of each TKI. First-line afatinib was available since October 2014 and the proportion of patients who were treated with this drug as a first-line therapy was similar in both groups (23% \[5/21\] in TB group and 24% \[16/67\] in non-TB group). The number of patients who received firstline EGFR-TKIs and EGFR-TKIs used was distributed throughout the study period, and they are summarized in [S1 Table](#SD1-crt-2018-084){ref-type="supplementary-material"}. The survival analyses results are summarized in [Table 5](#t5-crt-2018-084){ref-type="table"}. The median PFS of the 88 patients treated with EGFR-TKIs were 10.5 months (range, 4.6 to 21.2 months). In the univariate analysis, poor ECOG performance and advanced stage were significantly associated with shorter PFS. In addition, pulmonary TB lesions was significantly associated with shorter PFS (9.1 months vs. 11.6 months, p=0.020). Multivariate analysis showed that advanced stage (HR, 1.76; 95% CI, 1.10 to 2.83) and old TB lesions (HR, 1.85; 95% CI, 1.16 to 3.56) were independently associated with shorter PFS. The Kaplan-Meier survival curves also showed that patients with old TB lesions were likely to have shorter PFS ([Fig. 1A](#f1-crt-2018-084){ref-type="fig"}). The median OS of the 88 patients were 21.5 months (range, 5.1 to 39.6 months). In the univariate analysis, ever smoking and advanced stage were associated with shorter OS. In addition, TB lesions was also associated with shorter OS (19.4 months vs. 24.5 months, p=0.014). Multivariate analysis showed that ever smoking (HR, 2.02; 95% CI, 1.47 to 3.84), advanced stage (HR, 1.84; 95% CI, 1.09 to 3.10) and old TB lesions (HR, 1.60; 95% CI, 1.16 to 3.74) were independently associated with shorter OS. The Kaplan-Meier survival curves also showed that patients with old TB lesions were likely to have shorter OS ([Fig. 1B](#f1-crt-2018-084){ref-type="fig"}).

Discussion
==========

The current data demonstrate that pre-existing TB lesions are significantly associated with increased rate of *EGFR* mutation, especially exon 19 deletions in patients with lung adenocarcinoma. The mutation rate is significantly higher in patients carrying the main mass at the same lobe or in a different lobe of the ipsilateral lung with the main TB lesion compared with those who had main mass in the contralateral lung. In addition, patients with TB-related adenocarcinoma showed a poor treatment response and survival compared with non-TB-related counterparts when treated with EGFR-TKIs. To the best of our knowledge, this is the second study demonstrating the association between pulmonary TB and the *EGFR* mutational status and the first study identifying the clinical impact of pulmonary TB on the clinical outcome of patients treated with first-line EGFR-TKIs for EGFR mutated lung adenocarcinoma.

It has been known that benign lung diseases such as COPD, IPF and TB are independently associated with the risk of lung cancer \[[@b23-crt-2018-084]\]. The mechanisms underlying the role of those diseases on lung cancer risk are still unclear; however, chronic inflammation seems to be a major contributor. A meta-analysis of 37 case-control and four cohort studies showed 1.8-fold increased risk of lung cancer among patients with pulmonary TB \[[@b24-crt-2018-084]\]. In that study, the association was significant only with adenocarcinoma, while no significant associations with squamous or small cell type of lung cancer were observed \[[@b24-crt-2018-084]\]. In a recent large-scale population-based cohort study using patient care data of Taiwan, the incidence of lung cancer was approximately 11-fold higher in the population with a history of TB compared with those without past TB (26.3 vs. 2.4 per 10,000 person-years) \[[@b25-crt-2018-084]\]. The HR was 4.37 (95% CI, 3.56 to 5.36) for the TB cohort after adjusting for demographic variables \[[@b25-crt-2018-084]\].

In the present study, 21% of all the study population carried old TB lesions revealed by chest CT. This proportion was much higher than expected before the study. Previous studies reported that 2.1% to 13.1% of lung cancer patients had pre-existing TB \[[@b24-crt-2018-084]-[@b26-crt-2018-084]\]. However, the prevalence of preexisting TB in those studies may be underestimated as they collected TB information indirectly using International Classification of Diseases (ICD) codes from the nationwide database or a relatively small set of autopsy cases rather than a comprehensive review of chest images of lung cancer patients as reported in our present study. In a study of Taiwanese lung cancer cohort in which patients' chest CT was reviewed, the prevalence of old TB lesions in lung cancer patients was approximately 26% \[[@b27-crt-2018-084]\], which was comparable to our current data. As Taiwan and Korea are endemic areas for TB, the high rates of old TB lesions among the lung cancer patients were attributed to the high prevalence of TB in both countries. Further large-scale investigation is warranted to confirm whether this rate reflected the prevalence in the general population or merely indicated regional trends.

Although TB-related chronic inflammation is believed to be a main mechanism of lung carcinogenesis, whether previous pulmonary TB is associated with increased rate of driving mutations of lung cancer is largely unknown. As Korea is an endemic area of TB with an incidence of 100 per 100,000 individuals \[[@b28-crt-2018-084]\] and known for high *EGFR* mutation rate in lung cancer \[[@b13-crt-2018-084]\], we had postulated that previous pulmonary TB infection may affect to the increased *EGFR* mutation rate in Korean population. Our data showed that *EGFR* mutation was more frequent in patients with old TB lesions than those without. Moreover, *EGFR* mutations were detected at a higher frequency in patients carrying the main cancer mass in the same lobe or in a different lobe of the ipsilateral lung containing the main TB lesions compared with those who did not. Those results are consistent with those of a previous study demonstrating a high occurrence of lung cancer in the lung ipsilateral to the old TB lesion and the risk of ipsilateral lung cancer remained elevated throughout the follow-up period \[[@b29-crt-2018-084]\]. Although further studies are required, those previous findings and ours suggest that TB-associated chronic and local inflammation may be involved in lung carcinogenesis by provoking genetic alterations including *EGFR* mutations.

To date, only a single study evaluated the association between previous pulmonary TB and frequency of *EGFR* mutation in lung cancer. Luo et al. \[[@b27-crt-2018-084]\] evaluated the association in 275 Taiwanese patients whose *EGFR* mutation results were available. In their study, overall 191 patients (69.5%) had *EGFR* mutations and the *EGFR* mutation rate was significantly higher in patients with old TB lesions compared to those without the lesions (80.6% vs. 65.5%, p=0.018). In addition, they reported a high rate of exon 19 deletions in patients with old TB lesions that those without (68% vs. 34%, p \< 0.001). Although the higher rate of *EGFR* mutation in patients with old TB lesions is in line with our study, the mutational frequency of the total population (69.5%) was much higher than that of our population (39%) and that of a previously report on Taiwanese population \[[@b13-crt-2018-084]\]. We enrolled much more patients with available *EGFR* mutation results (n=477) and the overall frequency of *EGFR* mutations was similar to that of a previous study \[[@b13-crt-2018-084]\]. In terms of survival, Luo et al. \[[@b27-crt-2018-084]\] reported poorer 1-year survival rate in patients with old TB lesions than those without (77% vs. 85%, p=0.015). In addition, the poor survival rate of patients with TB lesions was consistent regardless of *EGFR* mutational status. These are different from our findings demonstrating no OS differences between the two groups. This discrepancy can be explained by different characteristics of study populations in the two studies. In Luo et al.'s study \[[@b27-crt-2018-084]\], most patients had locally advanced or metastatic cancers (83%) and many of them were treated with EGFR-TKIs (79.3%). However, our patients were evenly distributed in terms of stage, and thus 53% of them had advanced diseases and 30% were treated with EGFR-TKIs during their clinical course. The differential survival between the two groups in the previous study by Luo et al. can be attributed to TKIs treatment in advanced diseases rather than the true effect of pulmonary TB on the prognosis of lung cancers of different stages. Whether previous pulmonary TB is a prognostic factor in lung cancer warrants further investigations.

We demonstrated poor clinical outcome in patients with old TB lesions receiving EGFR-TKIs as a first-line treatment compared to those without TB lesions. In a retrospective cohort study by Chang et al. \[[@b30-crt-2018-084]\] reviewing 8,265 patients from National Health Insurance Research Database of Taiwan, pulmonary TB history was associated with poor clinical response to EGFR-TKIs in male patients but with a better response in female patients. However, this study has limitations associated with heterogeneous patient data as all patients who received TKIs were enrolled regardless of *EGFR* mutational status or lines of treatment. In our study, we analyzed the PFS and OS of patients who were treated with first-line EGFR-TKIs for *EGFR*-mutated lung adenocarcinomas. Our results showing poorer PFS and OS in patients with old TB lesions treated with EGFR-TKIs are partly consistent with aforementioned data. Although evaluation of genderbased impact was not possible because of the small population in our treatment group, the previous and our data suggest that pulmonary TB may adversely affect the TKI response in patients with *EGFR*-mutated pulmonary adenocarcinoma. The reason for the poor response to EGFR-TKIs in TB-related lung cancer is not clear; however, aggressive phenotype induced by chronic inflammation may be a possible explanation. Zhang et al. \[[@b19-crt-2018-084]\] demonstrated that chronic TB infection upregulated epiregulin, which correlated with the invasiveness of *EGFR*-mutant lung cancer. Further investigations are required to elucidate the mechanism of adverse effect of previous TB to TKI treatment.

There are several limitations in our study. First, this is a retrospective study in which selection bias is inevitable. Second, cumulative incidence of lung cancer in TB patients or dominant histologic types in TB-related lung cancer could not be evaluated in our population. Third, we provided only limited information on other genetic alterations including *ALK* rearrangement or *KRAS* mutation. Comprehensive genomic analysis using next-generation sequencing of large cohorts may elucidate the clinical impact of pulmonary TB on the development of genetic alterations during lung carcinogenesis. To confirm our findings and evaluate the association between previous pulmonary TB and genetic alternations of lung cancer, we have initiated data collection from the National Health Insurance Service Database of our country.

In summary, the current data suggest that pulmonary TB influences not only the *EGFR* mutational status but also treatment response of the patients treated with EGFR-TKIs. Our findings highlight the clinical implications of previous pulmonary TB during lung carcinogenesis and on the clinical outcome after lung cancer treatment, and warrant future investigations for the mechanism of poor response to TKIs and the relevance with a variety of genetic alterations in TB-related lung adenocarcinoma.
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![Kaplan-Meier survival curves for progression-free survival (A) and overall survival (B) in patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for *EGFR*-mutated lung adenocarcinoma. p-values were determined using the log-rank test. PFS, progression-free survival; OS, overall survival; TB, tuberculosis.](crt-2018-084f1){#f1-crt-2018-084}

###### 

Characteristics of study population

                                                                           No. of patients (%)   Groups     p-value    
  ------------------------------------------------------------------------ --------------------- ---------- ---------- -------
  **All**                                                                  477 (100)             100 (21)   377 (79)   
  **Sex**                                                                                                              
   Female                                                                  197 (41)              37 (37)    160 (42)   0.077
   Male                                                                    280 (59)              63 (63)    217 (58)   
  **Age (yr)**                                                                                                         
   \< 65                                                                   304 (64)              43 (43)    172 (46)   0.531
   ≥ 65                                                                    173 (36)              57 (57)    205 (54)   
  **Smoking**                                                                                                          
   Never                                                                   205 (43)              33 (33)    172 (46)   0.061
   Ever                                                                    272 (57)              67 (67)    205 (54)   
  **ECOG performance status**                                                                                          
   0, 1                                                                    395 (83)              80 (80)    315 (84)   0.692
   ≥ 2                                                                     82 (17)               20 (20)    62 (16)    
  **Stage**                                                                                                            
   I-IIIA                                                                  225 (47)              60 (60)    165 (44)   0.084
   IIIB-IV                                                                 252 (53)              40 (40)    212 (56)   
  **Location of primary cancer mass**                                                                                  
   Central                                                                 114 (24)              22 (22)    92 (24)    0.318
   Peripheral                                                              362 (76)              78 (78)    284 (76)   
  **Location of old TB lesion and cancer**                                                                             
   Ipsilateral another lobe                                                38 (38)               38 (38)    \-         \-
   Same lobe                                                               36 (36)               36 (36)    \-         
   Contralateral lung                                                      26 (26)               26 (26)    \-         
  **Underlying systemic diseases**                                                                                     
   None                                                                    207 (44)              43 (43)    164 (44)   0.457
   HTN/IHD                                                                 182 (39)              39 (39)    143 (38)   
   DM                                                                      27 (6)                6 (6)      21 (6)     
   CKD                                                                     15 (3)                5 (5)      10 (3)     
   Others                                                                  37 (8)                3 (3)      34 (9)     
  **Underlying lung diseases**                                                                                         
   None                                                                    413 (87)              82 (82)    330 (88)   0.096
   COPD                                                                    42 (9)                11 (11)    31 (8)     
   ILD                                                                     15 (3)                4 (4)      8 (2)      
   Bronchiectasis                                                          7 (1)                 3 (3)      6 (2)      
  ***KRAS*^[a)](#tfn1-crt-2018-084){ref-type="table-fn"}^**                                                            
   Wild-type                                                               177 (89)              43 (91)    132 (88)   0.341
   Mutated                                                                 22 (11)               4 (9)      18 (12)    
  ***ALK* translocation^[a)](#tfn1-crt-2018-084){ref-type="table-fn"}^**                                               
   Absent                                                                  228 (95)              45 (100)   183 (95)   0.533
   Present                                                                 10 (5)                0          10 (5)     
  ***EGFR***                                                                                                           
   Wild-type                                                               294 (61)              44 (44)    250 (66)   0.038
   Mutated                                                                 183 (39)              56 (56)    127 (34)   
    Exon19 deletion                                                        93 (19)               33 (33)    60 (16)    
    L858R mutation                                                         78 (16)               20 (20)    58 (14)    
    Other sites                                                            12 (3)                3 (3)      9 (5)      
  **EGFR-TKI use (any treatment lines)**                                                                               
   No                                                                      330 (69)              68 (68)    262 (69)   0.956
   Yes                                                                     147 (31)              32 (32)    115 (31)   

ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IHD, ischemic heart disease; DM, diabetes mellitus; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease, KRAS, Kirsten rat sarcoma; ALK, anaplastic lymphoma kinase; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor.

*KRAS* mutation and *ALK* translocation data were available in 199 and 238 patients, respectively.

###### 

Analysis results for the factors affecting frequency of *EGFR* mutations

                       Univariate analysis   Multivariate analysis                      
  -------------------- --------------------- ----------------------- ------------------ -------
  **Sex**                                                                               
   Female              2.65 (1.08-1.93)      \< 0.001                1.21 (1.05-1.86)   0.034
   Male                Reference                                     Reference          
  **Age (yr)**                                                                          
   \< 65               2.14 (1.57-2.76)      0.163                   1.08 (0.64-2.13)   0.521
   ≥ 65                Reference                                     Reference          
  **Smoking**                                                                           
   Never               1.82 (1.13-2.17)      \< 0.001                1.27 (1.12-1.98)   0.044
   Ever                Reference                                     Reference          
  **Old TB lesions**                                                                    
   No                  Reference             0.014                   Reference          0.031
   Yes                 1.79 (1.15-2.24)                              1.43 (1.08-2.47)   

EGFR, epidermal growth factor receptor; OR, odds ratio; CI, confidence interval; TB, tuberculosis.

Univariate analysis p-value by log-rank test,

Multivariate analysis p-value by Cox regression.

###### 

Frequency of *EGFR* mutations according to the spatial relationship between the primary lung mass and old TB lesions in the TB group

                                               *EGFR* mutation   Exon 19 mutation                                              
  -------------------------------------------- ----------------- ------------------ --------- ------- ---- --------- --------- -------
  **Location of lung cancer and TB lesions**                                                                                   
   Same lobe                                   38                23 (61)            15 (39)   0.028   30   17 (57)   13 (43)   0.013
   Ipsilateral different lobe                  36                26 (72)            10 (28)           27   14 (52)   13 (48)   
   Contralateral lung                          26                7 (27)             19 (73)           20   2 (10)    18 (90)   

Values are presented as number (%). EGFR, epidermal growth factor receptor; TB, tuberculosis.

###### 

Overall survival analyses results according to clinicopathological parameters of all study subjects

                                                                           Median overall survival (mo)   Univariate analysis   Multivariate analysis                      
  ------------------------------------------------------------------------ ------------------------------ --------------------- ----------------------- ------------------ ----------
  **All**                                                                  40.5                                                                                            
  **Sex**                                                                                                                                                                  
   Female                                                                  49.3                           Reference             0.007                   Reference          0.204
   Male                                                                    28.9                           1.47 (1.05-3.19)                              1.19 (0.74-3.72)   
  **Age (yr)**                                                                                                                                                             
   \< 65                                                                   53.4                           Reference             0.003                   Reference          0.158
   ≥ 65                                                                    29.1                           1.55 (1.16-2.07)                              1.26 (0.91-1.75)   
  **Smoking**                                                                                                                                                              
   Never                                                                   46.7                           Reference             0.031                   Reference          0.910
   Ever                                                                    27.8                           1.38 (1.04-1.85)                              1.18 (0.60-1.61)   
  **ECOG performance status**                                                                                                                                              
   0, 1                                                                    53.3                           Reference             \< 0.001                Reference          0.008
   ≥ 2                                                                     13.1                           3.75 (2.72-5.16)                              1.67 (1.14-2.43)   
  **Stage**                                                                                                                                                                
   I-IIIA                                                                  101.4                          Reference             \< 0.001                Reference          \< 0.001
   IIIB-IV                                                                 18.3                           5.79 (4.06-8.28)                              3.61 (2.31-5.64)   
  **Underlying systemic diseases**                                                                                                                                         
   None                                                                    43.3                           Reference             0.112                   Reference          0.457
   Yes                                                                     26.7                           1.61 (0.89-2.90)                              1.14 (0.45-2.47)   
  **Underlying lung diseases other than TB**                                                                                                                               
   None                                                                    44.3                           Reference             0.226                   NA                 
   Yes                                                                     24.8                           1.75 (0.98-2.11)                                                 
  ***KRAS*^[c)](#tfn6-crt-2018-084){ref-type="table-fn"}^**                                                                                                                
   Wild-type                                                               40.5                           Reference             0.759                   NA                 
   Mutated                                                                 31.0                           1.09 (0.57-2.10)                                                 
  ***ALK* translocation^[c)](#tfn6-crt-2018-084){ref-type="table-fn"}^**                                                                                                   
   Absent                                                                  46.0                           Reference             0.737                   NA                 
   Present                                                                 28.8                           1.42 (0.26-2.62)                                                 
  ***EGFR***                                                                                                                                                               
   Wild-type                                                               24.1                           1.97 (1.04-3.65)      \< 0.001                1.91 (1.29-3.58)   \< 0.001
   Mutated                                                                 59.0                           Reference                                     Reference          
  **EGFR-TKI use (any treatment lines)**                                                                                                                                   
   No                                                                      46.4                           Reference             0.699                   NA                 
   Yes                                                                     37.5                           1.06 (0.79-1.43)                                                 
  **Old TB lesions**                                                                                                                                                       
   No                                                                      45.2                           Reference             0.154                   Reference          0.273
   Yes                                                                     38.1                           1.32 (0.59-1.77)                              1.18 (0.47-2.65)   

HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; TB, tuberculosis; KRAS, Kirsten rat sarcoma; ALK, anaplastic lymphoma kinase; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NA, not analyzed.

Univariate analysis p-value by log-rank test,

Multivariate analysis p-value by Cox regression,

*KRAS* mutation and *ALK* translocation data were available in 199 and 238 patients, respectively.

###### 

Survival analyses results according to clinicopathologic parameters in patients treated with first-line EGFR-TKIs

                       No. of patients (%)   PFS    OS                                         
  -------------------- --------------------- ------ ------- ------------------- ------ ------- -------------------
  **All**              88 (100)              10.5                               21.5           
  **Sex**                                                                                      
   Female              23 (26)               11.1   0.254   NA                  22.8   0.215   NA
   Male                65 (74)               9.4                                21.1           
  **Age (yr)**                                                                                 
   \< 65               31 (35)               10.6   0.606   NA                  23.6   0.099   Reference
   ≥ 65                57 (65)               9.5                                20.3           1.18 (0.73- 1.93)
  **Smoking**                                                                                  
   Never               25 (28)               9.8    0.311   NA                  24.6   0.003   Reference
   Ever                63 (72)               10.3                               19.0           2.02 (1.47- 3.84)
  **ECOG PS**                                                                                  
   0, 1                59 (67)               11.8   0.048   Reference           23.7   0.203   NA
   ≥ 2                 29 (33)               9.6            1.27 (0.79-2.05)    21.2           
  **Stage**                                                                                    
   IIIB                25 (28)               11.9   0.019   Reference           24.8   0.011   Reference
   IV                  63 (72)               8.9            1.76 (1.10- 2.83)   18.1           1.84 (1.09- 3.10)
  **Old TB lesions**                                                                           
   No                  67 (76)               11.6   0.020   Reference           24.5   0.014   Reference
   Yes                 21 (24)               9.1            1.85 (1.16- 3.56)   19.4           1.60 (1.16- 3.74)

EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; NA, not analyzed; ECOG, Eastern Cooperative Oncology Group; PS, performance status; TB, tuberculosis.
